EATG » Cure

Cure

2016 i-Base/TAG Pipeline Report

Latest annual review on HIV and TB drugs, diagnostics, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in development The 2016 Pipeline Report was launched on…

Treatment targets HIV’s last hiding place

Genetically engineered protein helps immune system see and kill cells containing dormant HIV UK scientists may have found a way to destroy HIV's last refuge. A study by Oxford University…

HIV “safe houses” identified

Researchers from the University of Montreal Hospital Research Center (CRCHUM) have identified cells that provide “safe houses” for the human immunodeficiency virus (HIV) during antiretroviral therapy (ART). "We have found…

Sugar-binding protein galectin-9 found to be a new weapon to cure HIV

July 13, 2016, San Francisco, CA -- The ultimate impediment to a cure for HIV infection is the presence of latent, HIV-infected cells, which can reawaken and produce new virus…

NIH expands investment in HIV cure research

Six research teams to lead collaborative investigations worldwide The National Institutes of Health has awarded approximately $30 million in annual funding over the next five years to six research collaborations…

International AIDS Society releases new strategy to guide global HIV cure research

Geneva, Switzerland, 11 July 2016 -- A comprehensive new strategy, developed by the International AIDS Society (IAS) and published online today in the journal Nature Medicine, presents key priorities for…

“Towards an HIV Cure” workshop at the AIDS2016 Conference on 16/07/2016

The final program of the "Towards an HIV Cure" Workshop held in connection with the AIDS2016 Conference in Durban on 16 July 2016 is now online. Co-organised by the European AIDS…

ViiV Healthcare joins PENTA Foundation in search for strategies to achieve remission in children living with HIV

EPIICAL Consortium looks to develop predictive models to optimise treatment London, UK, Rome and Padua, Italy, 29 June 2016 – ViiV Healthcare, the global specialist HIV company majority owned by…

HIV antibody 3BNC117 delays viral rebound, could be component of cure

The injectable broadly neutralizing antibody 3BNC117 suppressed HIV and delayed viral rebound for up to 19 weeks among people with the virus who went off their antiretrovirals (ARVs), The Los…

Study observes potential breakthrough in treatment of HIV

A new study conducted by researchers at the San Francisco VA Medical Center (SFVAMC) observes that pharmacological enhancement of the immune systems of HIV patients could help eliminate infected cells,…